Drug Profile

RM 853

Alternative Names: RM-853; T-3525770

Latest Information Update: 28 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Takeda
Developer Rhythm; Takeda
Class Obesity therapies
Mechanism of Action Ghrelin O-acyltransferase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Prader-Willi syndrome

Most Recent Events

28 May 2022 No recent reports of development identified for preclinical development in Prader-Willi-syndrome in USA (PO)
31 Dec 2020 Rhythm Pharmaceuticals in-licenses patent family from Takeda, prior to December 2020
31 Dec 2020 Rhythm has patent protection for composition of matter and methods of use of RM 853 in USA and other countries, including China, Europe, and Japan, prior to December 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com